Pascale Boissel appointed new member of Innate’s Supervisory    Board Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) announces the results of the vote of its shareholders at the Annual General Meeting (“AGM”) which took place on May 19,

Phase II expansion cohort of “IO-pretreated patients” demonstrates 20% overall response rate Data confirm previous preliminary efficacy data seen in this subpopulation Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that it

Cash, cash equivalents and financial assets of the Company amounted to €206.9 million i First patient dosed in avdoralimab (anti-C5aR) Phase II clinical trial in COVID-19 patients with severe pneumonia First patient dosed in IPH5201 Phase I clinical trial in advanced solid tumors New efficacy data